Orphazyme withdraws marketing application ahead of final vote
On Tuesday, biotech company Orphazyme announced that it is withdrawing its European marketing application for arimoclomol within the Niemann-Pick type C indication, ahead of the final vote of an EMA expert committee.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Biotech company Orphazyme has decided to withdraw its European marketing authorization application for its drug hope, arimoclomol, a potential treatment for Niemann-Pick type C (NPC), a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
Orphazyme files for delisting in US
For subscribers
.jpg&w=384&q=75)
